Molidustat Tablets – HIF-PH Inhibitor for Anemia Management in Cats with Chronic Kidney Disease (CKD)
- In stock, ready to ship
- Worldwide Shipping
- Fast Delivery (In 8-15 Days)
- 14-Days Money Back
- Secure Checkout
Pairs well with
Oral Anaemia Management for Cats with Chronic Kidney Disease
Anaemia is one of the most debilitating complications of feline CKD — leaving cats weak, lethargic, and unable to enjoy daily life. Molidustat is a next-generation oral HIF prolyl hydroxylase (HIF-PH) inhibitor that stimulates your cat's own body to produce more erythropoietin (EPO) and red blood cells — without the need for injectable ESA therapy.
How Molidustat Works
Molidustat inhibits prolyl hydroxylase enzymes, stabilizing HIF-α (Hypoxia-Inducible Factor) under normal oxygen conditions. This activates the body's natural oxygen-sensing pathway, triggering:
- Increased endogenous erythropoietin (EPO) production from the kidneys
- Enhanced iron metabolism and utilization for red blood cell synthesis
- Stimulation of erythropoiesis in the bone marrow
Unlike injectable recombinant EPO, Molidustat promotes a more physiologic and sustained erythropoietic response — working with the body's own biology rather than replacing it.
Why Choose Molidustat?
- Oral tablet formulation — no injections, reducing stress for cats and owners alike
- Stimulates natural EPO production — activates the HIF pathway for a physiologic erythropoietic response
- Sustained red blood cell support — stable, ongoing stimulation of erythropoiesis over time
- Targets the root cause — addresses the EPO deficiency underlying CKD-related anaemia
- Convenient dosing — small 25 mg tablets easy to administer with food
Product Details
- Active Ingredient: Molidustat 25 mg per tablet
- Pack Size: 10 tablets
- Indication: Off-label management of non-regenerative anaemia associated with CKD in cats
Important Safety Information
Molidustat is intended for off-label veterinary use only and must be prescribed and monitored by a licensed veterinarian. Regular haematological monitoring (PCV/haematocrit) is recommended throughout treatment to assess response and adjust dosing. Not for use in humans.